Venous Thromboembolism Treatment Market: By Drug Type ( Factor Xa inhibitors, Thrombolytic therapy,Plasminogen activators,Fondaparinux,Dabigatran,Warfarin), By Disease Type ( Deep vein thrombosis, Pulmonary embolism), By Distribution Channel (Hospital pharmacies, Online Pharmacies, Retail pharmacies) - Geography    

Purchase Option

$ 4400
$ 6600
$ 8900

Venous Thromboembolism Treatment Market size was valued at USD 1.32 billion in 2022 and is poised to grow at a significant CAGR of 9.0% from 2023-29. Venous thromboembolism is a disease caused by the clotting of blood in the blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years. People with overweight, persons with thicker blood and the persons suffering from autoimmune disorders such as (lupus, rheumatoid arthritis etc.) or cancer are at higher risk of venous thromboembolism. Venous thromboembolism can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, oedema, fever, tachycardia, and dyspnoea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral veins. The growth of global venous thromboembolism treatment market is due to rise in prevalence of venous thromboembolism (According to the International Society of Thrombosis and Haemostasis, Inc.(ISTH), approximately 10 Mn cases of venous thromboembolism occur annually). The most commonly adopted strategies by industry players include new product launches with technological innovations, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism treatment market share.

Venous Thromboembolism Treatment Market Key Developments : 

  • In March 2017, The Apex trial reported that extended use of betrixaban beyond the parenteral prophylaxis with enoxaparin reduces the venous thromboembolism incidence among the patients.
  • In May 2011, Eliquis (apixaban) Approved In Europe for preventing venous thromboembolism after elective knee or hip replacement.
  • In January 2015, Bayer  forms the collaboration with academic and governmental institutions for Rivaroxaban study in patients with a recent embolic stroke of undetermined source.

Global Venous Thromboembolism Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9%

Largest Market

North-America

Fastest Growing Market

Europe
Venous Thromboembolism Treatment Market Dynamics

Increase in the incidence of venous thromboembolism are fuelling the Venous Thromboembolism (VTE) Treatment Market. Furthermore, increase in surgical procedures such as hip and knee replacements that are risk factors for venous thromboembolism conditions, growing patient awareness venous thromboembolism conditions expected to boost the venous thromboembolism treatment market growth over the forecast period. However, a high cost of deep vein thrombosis treatment, high unmet needs of currently available treatment procedures, and adverse effects associated with drugs hinder the growth of venous thromboembolism treatment market. Similarly, stringent regulatory approvals, the presence of alternatives treatments such as thrombectomy and percutaneous techniques are hindering the growth of venous thromboembolism drugs market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Venous Thromboembolism Treatment Market Segmentation

By Drug Type
  • Factor Xa inhibitors
  • Thrombolytic therapy
  • Plasminogen activators
  • Fondaparinux
  • Dabigatran
  • Warfarin
By Disease Type
  • Deep vein thrombosis
  • Pulmonary embolism
By Distribution Channel
  • Hospital pharmacies
  • Online Pharmacies
  • Retail pharmacies

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Venous Thromboembolism Treatment Market size was valued at USD 1.32 billion in 2022 and is poised to grow at a significant CAGR of 9.0% from 2023-29.

key trend of the Venous Thromboembolism (VTE) Treatment Market is the increasing adoption of direct oral anticoagulants (DOACs) as a preferred treatment option over traditional therapies like warfarin, driven by their convenience and reduced need for monitoring.

One key threat in the Venous Thromboembolism Treatment Market is the risk of bleeding complications associated with anticoagulant therapies, which may limit their use in certain patient populations.

1. Executive summary
2. Global Venous Thromboembolism Market Introduction
2.1. Global Venous Thromboembolism Market - Taxonomy
2.2. Global Venous Thromboembolism Market -Definitions
2.2.1. Drug Type
2.2.2. Disease Type
2.2.3. End User
3. Global Venous Thromboembolism Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Venous Thromboembolism Market Dynamics - Factors Impact Analysis
3.6. Global Venous Thromboembolism Market - Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Venous Thromboembolism Market - Product Innovations
4. Global Venous Thromboembolism Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Global Venous Thromboembolism Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Venous Thromboembolism (VTE) Treatment Market Oppurtunity Analysis
5. Global Venous Thromboembolism Market, By Drug Type, 2018 - 2022 and Forecast, 2023 - 2029
5.1. Factor Xa inhibitors
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Thrombolytic therapy
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Plasminogen activators
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Fondaparinux
5.4.1. Global Venous Thromboembolism Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Dabigatran
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
5.6. Warfarin
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.6.3. Market Opportunity Analysis
6. Global Venous Thromboembolism Market Forecast, By Disease Type, 2018 - 2022 and Forecast, 2023 - 2029
6.1. Deep Vein Thrombosis
6.1.1. Global Venous Thromboembolism Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
6.2. Pulmonary Embolism
6.2.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
7. Global Venous Thromboembolism Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029
7.1. Hospital pharmacies
7.2. Online Pharmacies
7.3. Retail pharmacies
7.3.1. Global Venous Thromboembolism Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. Global Venous Thromboembolism Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029
8.1. North America
8.1.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
8.2. Europe
8.2.1. Global Venous Thromboembolism Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
8.4. Latin America
8.4.1. Global Venous Thromboembolism Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Venous Thromboembolism Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2023 - 2029
9. North America Venous Thromboembolism Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
9.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Factor Xa inhibitors
9.1.2. Thrombolytic therapy
9.1.3. Plasminogen activators
9.1.4. Fondaparinux
9.1.5. Dabigatran
9.1.6. Warfarin
9.2. Disease Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Deep vein thrombosis
9.2.2. Pulmonary embolism
9.3. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Retail Pharmacies
9.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2023 - 2029
9.6. North America Venous Thromboembolism Market Dynamics - Trends 
10. Europe Venous Thromboembolism Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
10.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Factor Xa inhibitors
10.1.2. Thrombolytic therapy
10.1.3. Plasminogen activators
10.1.4. Fondaparinux
10.1.5. Dabigatran
10.1.6. Warfarin
10.2. Disease Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Deep vein thrombosis
10.2.2. Pulmonary embolism
10.3. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Online Pharmacies
10.3.3. Retail Pharmacies
10.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2023 - 2029
10.6. Europe Venous Thromboembolism Market Dynamics - Trends
11. Asia-Pacific Venous Thromboembolism Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
11.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Factor Xa inhibitors
11.1.2. Thrombolytic therapy
11.1.3. Plasminogen activators
11.1.4. Fondaparinux
11.1.5. Dabigatran
11.1.6. Warfarin
11.2. Disease Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Deep vein thrombosis
11.2.2. Pulmonary embolism
11.3. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2023 - 2029
11.6. Europe Venous Thromboembolism Market Dynamics - Trends
12. Latin America Venous Thromboembolism Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
12.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Factor Xa inhibitors
12.1.2. Thrombolytic therapy
12.1.3. Plasminogen activators
12.1.4. Fondaparinux
12.1.5. Dabigatran
12.1.6. Warfarin
12.2. Disease Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Deep vein thrombosis
12.2.2. Pulmonary embolism
12.3. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Online Pharmacies
12.3.3. Retail Pharmacies
12.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2023 - 2029
12.6. Latin America Venous Thromboembolism Market Dynamics - Trends
13. Middle East and Africa Venous Thromboembolism Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
13.1. Drug Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Factor Xa inhibitors
13.1.2. Thrombolytic therapy
13.1.3. Plasminogen activators
13.1.4. Fondaparinux
13.1.5. Dabigatran
13.1.6. Warfarin
13.2. Disease Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Deep vein thrombosis
13.2.2. Pulmonary embolism
13.3. Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Online Pharmacies
13.3.3. Retail Pharmacies
13.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2023 - 2029
13.6. MEA Venous Thromboembolism Market Dynamics - Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Sanofi (France)
14.2.2. Pfizer Inc. (U.S.)
14.2.3. Daiichi Sankyo Co. Ltd. (Japan)
14.2.4. Bristol Myers Squibb (U.S.)
14.2.5. Johnson & Johnson Services, Inc. (U.S.)
14.2.6. AbbVie Inc. (U.S.)
14.2.7. Merck & Co. (U.S.)
14.2.8. Astellas Pharma Inc. (Japan)
14.2.9. Sawai Pharmaceuticals Co. Ltd. (U.S.)
14.2.10. Abbott Laboratories (U.S.)
14.2.11. Wockhardt Ltd (India)
14.2.12. Bayer AG (Germany)
14.2.13. Dupont Pharm Co. (U.S.)
15. Research Methodology
16. Key Assumptions and Acronyms
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • Daiichi Sankyo Co. Ltd. (Japan)
  • Bristol Myers Squibb (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Merck & Co. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • Sawai Pharmaceuticals Co. Ltd. (U.S.)
  • Abbott Laboratories (U.S.)
  • Wockhardt Ltd (India)
  • Bayer AG (Germany)
  • Dupont Pharm Co. (U.S.)

Adjacent Markets